Evotec Investor Day Presentation Deck
evotec
Pipeline will strongly gain visibility with no clinical costs for us
Overview of pipeline and selected upcoming events & internal champions
Selected expected upcoming pipeline events in the
next 12 - 24 months
1. Phase Ilb with Bayer in RCC (Eliapixant)
2. Phase II with Bayer in Overactive bladder (Eliapixant)
3. Phase II with Bayer in Endometriosis (Eliapixant)
4. Phase II initiation with BI in Oncology / Pain
5.
Phase II with Bayer in Gynaecology (B1 antagonist)
6. Phase I initiation in Chikungunya virus
7. Phase I with BMS in CNS
8. Phase I with Exscientia in Oncology (A2a)
9. Phase I with Bayer in Gynaecology (P2X4)
10. Phase I with Sanofi in Immuno-oncology
11. Phase I in HBV Cure
PAGE 23
12. Multiple co-owned equity companies will progress in
clinic (e.g. Topas, Forge, Carrick, Fibrocor, QRbeta, ...)
"Beta cell therapy is the most promising approach to cure diabetes."
"IPSCs have game changing potential, they fast forward many key
questions for new drugs."
Andreas Scheel (Evotec) & Rainer Kuhn (Evotec)
"True innovation - an antibody to be used as both: targeted therapy, and
prophylactic treatment"
Florian von Groote-Bidlingmaier (Evotec)
"Potent molecule with sustained activity to achieve HBV functional cure."
Antoine Alam (Evotec)
"P2X3 is a pipeline in a molecule. E.g. in refractory chronic cough with its
selectivity and side effect profile."
Adam Davenport (Evotec)View entire presentation